Clinical Trial Update: (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis [Phase 2]

View source ↗

Summary

Phase 2 PATHFINDER study evaluating avapritinib in advanced systemic mastocytosis and related subtypes has completed with results posted, assessing efficacy and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Systemic Mastocytosis
• Mast Cell Leukemia
• Systemic Mastocytosis
• Systemic Mastocytosis with Associated Hematologic Neoplasm

Drugs mentioned

• Ayvakit (avapritinib) (avapritinib)

Snippet

Sponsor: Blueprint Medicines Corporation | Conditions: Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis | Phase 2 | Status: COMPLETED | Results posted: 2026-04-24